Global Allogeneic Cell Therapy Market Size is valued at 997.36 Million in 2022 and is predicted to reach 2853.34 Million by the year 2031 at a 12.7 % CAGR during the forecast period for 2023-2031. Allogeneic Cell Therapy Market Size, Share & Trends Analysis Report By Type of Cell Therapy (Virus-Specific T-Cell, Stem Cell, Regulatory T-Cell), By Source of Cell, By Target Indication, By Therapeutic Area, Region And Segment Forecasts, 2023 to 2...
Report ID: 1084 |
Delivery: Immediate |
Published: December 2025 |
No. of Pages: 180
Global Immuno-Oncology Cell Therapy Market Size is valued at USD 11.9 Billion in 2024 and is predicted to reach USD 95.3 Billion by the year 2034 at a 23.2% CAGR during the forecast period for 2025-2034. Immuno-oncology cell therapies are a remarkably promising treatment for a different types of cancer patients. The approval of CAR-T cell therapy products represents one of the most significant breakthroughs in cancer since the introduction of ...
Report ID: 1083 |
Delivery: Immediate |
Published: November 2025 |
No. of Pages: 180
Global AI-Based Clinical Trial Solution Providers Market Size is valued at USD 2.3 Billion in 2024 and is predicted to reach USD 16.6 Billion by the year 2034 at a 22.0% CAGR during the forecast period for 2025-2034. Artificial Intelligence is a set of smart technologies that develop and learn from data and perform tasks based on previous experience. The process, clinical trials are crucial that enable both innovators and regulators to assess ...
Report ID: 1082 |
Delivery: Immediate |
Published: March 2025 |
No. of Pages: 180
Rituximab Biosimilar Market is expected to grow at a 12.3% CAGR during the forecast period for 2025-2034. Rituximab is a chimeric anti-CD20 antibody that binds to the CD20 antigen present on the standard and malignant B cells surface. It is indicated for the treatment of blood cancer (CD20-positive) such as chronic lymphocytic leukemia and non-Hodgkin’s lymphoma, as well as an autoimmune disorder such as Rheumatoid arthritis. Rituximab i...
Report ID: 1081 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Trastuzumab Biosimilar Market is expected to grow at a 25.0 % CAGR during the forecast period for 2025-2034. Trastuzumab is a recombinant DNA-derived humanized monoclonal antibody that binds to human epidermal growth factor receptor 2 (HER2). HER2 is over expressed in some types breast cancer cells hence, trastuzumab is mainly indicated for the treatment of HER2 positive breast cancer as well as it is also approved for the treatment of metasta...
Report ID: 1080 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
The nerve growth factor is a tumor tissue produced growth factor that promotes the growth and differentiation of sympathetic and sensory ganglia. It is the first growth factor to be identified. An elevated level of nerve growth factor leads to inflammation and peripheral nerve injury. The nerve growth factor is secreted in the body following stimulus (eg, chemical, thermal, or mechanical). Clinically, an elevated level of nerve growth factor in t...
Report ID: 1079 |
Delivery: Immediate |
Published: November 2024 |
No. of Pages:
The Cancer Biosimilars Market is expected to grow at a 20.0 % CAGR during the forecast period for 2023-2031. Biosimilar is defined as a type of biological product that is approved by respective regulatory bodies because of its clinical similarity to already approved biological products. This is relatively cheaper than biologics. The abnormal growth of call is called cancer. Cancer is the second leading cause of death across the globe. Ma...
Report ID: 1078 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Global Abdominal Aorta Stent Grafts Market is expected to grow at a 4.9% CAGR during the forecast period for 2025-2034. The Aortic abdominal stent graft is used for abdominal aneurysm endovascular repair. Endovascular aneurysm repair (EVAR), is a new treatment option for abdominal aortic aneurysm in which a graft is inserted into the aorta to strengthen it. This surgery doesn’t need surgically opening the chest or abdomen and is done using...
Report ID: 1077 |
Delivery: Immediate |
Published: May 2025 |
No. of Pages: 170
Filgrastim Biosimilars Market Size is predicted to expand with a 8.5% CAGR during the forecast period for 2025-2034. Key Industry Insights & Findings from the Report: Governments around the world are promoting the use of biosimilars through various initiatives aimed at enhancing affordability and access. Filgrastim biosimilars have been shown to be effective and safe for managing neutropenia in cancer patients, which enhances their ado...
Report ID: 1076 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 175
Prevention of progression and proliferation of infectious diseases in the body has always been the point of discussion, which has developed a throng of techniques to alter these effects of the immune system. Immunotherapy is a treatment that uses particular parts of a person’s immune organism to fight against cancer. The immune system is a collection of special cells, organs and substances which protect us from diseases and infections. Immu...
Report ID: 1074 |
Delivery: Immediate |
Published: October 2024 |
No. of Pages: 140
Pharmaceuticals